Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00526630 · ClinicalTrials.gov registry record · Phase 4

Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

A Phase 4 study of Parkinson's Disease and Gait Impairment, sponsored by University of Cincinnati.

Completed
Registry status
Phase 4
Development phase
23
Enrollment target
1
Study location

NCT00526630 is a Phase 4 study of Parkinson's Disease and Gait Impairment that has completed, run by University of Cincinnati. The registered enrollment target is 23 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00526630, a Phase 4 study of Parkinson's Disease and Gait Impairment, has completed, sponsored by University of Cincinnati.

COMPLETED
Registry status
Phase 4
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to examine whether Methylphenidate (MPD) can result in improvement of gait (walking) in a population of Parkinson's Disease (PD) patients whose main disability is freezing of gait. MPD (Ritalin®) is a drug which can excite or stimulate certain systems of the body that control motor function. This drug is FDA approved for the treatment of attention hyperactivity disorder, a condition unrelated to PD. The researchers hypothesize that daily treatment with a tolerable daily oral dose of MPD will improve gait velocity, stride length, cadence, and decrease freezing of gait, 3 months from treatment initiation in patients with moderately advanced PD, whose gait impairment is an important source of disability despite optimized antiparkinsonian treatment.

Conditions Studied

Parkinson's Disease Gait Impairment

Interventions

  • DRUG Placebo
  • DRUG Methylphenidate (MPD)

Study Locations (1)

Ohio

  • University Neurology-Movement Disorders Clinic - Cincinnati

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2007-12
Est. Completion 2009-10
Phase Phase 4

Sponsor

University of Cincinnati

245 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00526630

The ClinicalTrials.gov registry entry for NCT00526630 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (96% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00526630 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00526630 about?

NCT00526630 is a clinical study titled "Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease". The purpose of this research study is to examine whether Methylphenidate (MPD) can result in improvement of gait (walking) in a population of Parkinson's Disease (PD) patients whose main disability is freezing of gait. MPD (Ritalin®) is a drug which can excite or stimulate certain systems of the bod...

What is the current status of trial NCT00526630?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2007-12. Estimated completion is 2009-10.

What conditions does trial NCT00526630 study?

This clinical trial studies the following conditions: Parkinson's Disease, Gait Impairment.

What interventions are being tested in trial NCT00526630?

The interventions under investigation include: Placebo (DRUG), Methylphenidate (MPD) (DRUG).

Who is sponsoring clinical trial NCT00526630?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00526630 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Gait Impairment

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.